866-997-4948(US-Canada Toll Free)

Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Global Clinical Trials Review, H2, 2018

Published By :

GlobalData

Published Date : Sep 2018

Category :

Pharmaceutical

No. of Pages : 124 Pages

Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Global Clinical Trials Review, H2, 2018

Summary

GlobalData's clinical trial report, Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Global Clinical Trials Review, H2, 2018" provides an overview of Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) clinical trials scenario. This report provides top line data relating to the clinical trials on Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) to Women's Health Clinical Trials 17
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 21
Clinical Trials by E7 Countries: Proportion of Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) to Women's Health Clinical Trials 23
Clinical Trials by Phase in E7 Countries 25
Clinical Trials in E7 Countries by Trial Status 26
Clinical Trials by Phase 28
In Progress Trials by Phase 29
Clinical Trials by Trial Status 30
Clinical Trials by End Point Status 32
Subjects Recruited Over a Period of Time 33
Clinical Trials by Sponsor Type 34
Prominent Sponsors 35
Top Companies Participating in Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials 37
Prominent Drugs 39
Clinical Trial Profile Snapshots 41
Appendix 123
Abbreviations 123
Definitions 123
Research Methodology 124
Secondary Research 124
About GlobalData 124
Contact Us 125
Source 125

List of Tables
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, Global, Clinical Trials by Region, 2018* 8
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 10
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 11
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 12
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 13
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials, North America, Top Countries, 2018* 14
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2018* 15
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials, Central and South America, Top Countries, 2018* 16
Proportion of Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) to Women's Health Clinical Trials, G7 Countries (%), 2018* 18
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 20
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 22
Proportion of Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) to Women's Health Clinical Trials, E7 Countries (%), 2018* 24
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 25
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 27
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, Global, Clinical Trials by Phase, 2018* 28
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 29
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 31
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 32
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 33
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 34
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 36
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 38
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 40

List of Figures
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, Global, Clinical Trials by Region (%), 2018* 8
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 11
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 12
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 13
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 14
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2018* 15
Proportion of Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) to Women's Health Clinical Trials, G7 Countries (%), 2018* 17
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 19
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 21
Proportion of Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) to Women's Health Clinical Trials, E7 Countries (%), 2018* 23
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 25
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 26
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 28
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 29
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 30
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 32
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 33
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 34
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 35
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 37
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 39
GlobalData Methodology 124

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *